Relationship of maternal obesity and vitamin D concentrations with fetal growth in early pregnancy

Zhang, Qianqian; Zhang, Chen; Wang, Yi; Zhao, Jianan; Li, Haiyuan; Shen, Qiwei; Wang, Xiaoli; Ni, Meng; Ouyang, Fengxiu; Vinturache, Angela; Chen, Hao; Liu, Zhiwei

doi:10.1007/s00394-021-02695-w

Cited by 14 publications

(11 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies assessed maternal levels of Vit-D during early pregnancy and its implications in fetal in utero growth and development. In a large retrospective cohort study of 15,651 pregnancies in China by Zhang et al [ 36 ], fetuses of Vit-D insufficient/deficient mothers during early pregnancy had a decreased crown–rump length, compared to the Vit-D sufficient group. In the same maternal group, the risk of early fetal growth restriction was also increased by 13%.…”

Section: Resultsmentioning

confidence: 99%

The Gestational Effects of Maternal Bone Marker Molecules on Fetal Growth, Metabolism and Long-Term Metabolic Health: A Systematic Review

Dimas

Politi

Bargiota

et al. 2022

IJMS

View full text Add to dashboard Cite

Fetal exposure in adverse environmental factors during intrauterine life can lead to various biological adjustments, affecting not only in utero development of the conceptus, but also its later metabolic and endocrine wellbeing. During human gestation, maternal bone turnover increases, as reflected by molecules involved in bone metabolism, such as vitamin D, osteocalcin, sclerostin, sRANKL, and osteoprotegerin; however, recent studies support their emerging role in endocrine functions and glucose homeostasis regulation. Herein, we sought to systematically review current knowledge on the effects of aforementioned maternal bone biomarkers during pregnancy on fetal intrauterine growth and metabolism, neonatal anthropometric measures at birth, as well as on future endocrine and metabolic wellbeing of the offspring. A growing body of literature converges on the view that maternal bone turnover is likely implicated in fetal growth, and at least to some extent, in neonatal and childhood body composition and metabolic wellbeing. Maternal sclerostin and sRANKL are positively linked with fetal abdominal circumference and subcutaneous fat deposition, contributing to greater birthweights. Vitamin D deficiency correlates with lower birthweights, while research is still needed on intrauterine fetal metabolism, as well as on vitamin D dosing supplementation during pregnancy, to diminish the risks of low birthweight or SGA neonates in high-risk populations.

show abstract

Section: Resultsmentioning

confidence: 99%

The Gestational Effects of Maternal Bone Marker Molecules on Fetal Growth, Metabolism and Long-Term Metabolic Health: A Systematic Review

Dimas

Politi

Bargiota

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…T. Karlsson et al (2015) повідомили, що незважаючи на більш високе споживання вітаміну Д з їжею та аналогічні добавки, вагітні жінки з ожирінням мали нижчий рівень вітаміну Д сироватки крові у першому триместрі, ніж вагітні жінки з нормальною вагою [12]. Взаємозв'язок між дефіцитом вітаміну Д та ожирінням може опосередковуватися кількома механізмами, включаючи зниження біодоступності вітаміну Д та посилення адипогенезу, що залежить від інгібування гамма-рецептора, активованого проліферативним пероксисом та підсилювача, що зв'язує білок альфа, який модулюється 1,25-гідроксивітаміном D через рецептори вітаміну Д [30].…”

Section: вступunclassified

“…Тоді, як при порівняльному аналізі нами було вста-новлено, що статистично вірогідний результат щодо розвитку перинатальної патології було відзначено у відношенні різниці показників між вагітними жінками, що мали попередньо-встановлену недостатність вітаміну Д і ІІІ підгрупи (вміст 25(ОН)D > 28,1 нг/мл) ВР 3,12, 95% ДІ [1,30], р=0,02 та практично-здоровими жінками ВР 13,0, 95% ДІ [1,[83][84][85][86][87][88][89][90][91][92]29], р=0,01. Вагітні жінки із першої клінічної підгрупи не мали достовірної відмінності за кількістю випадків патології вагітності щодо тотожних показників представниць з ІІІ підгрупи та жінок із контрольної групи ВР 1,56, 95% ДІ [0,50-4,86], р=0,44 та ВР 6,50, 95% ДІ [0,84-50,14], р=0,07, відповідно.…”

Section: результати обговоренняunclassified

The analysis of the clinical effectiveness of preventive therapy in pregnant women with moderate obesity and disorder of vitamin D metabolism

Bodnarchuk¹

2022

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

Annotation. Obesity during pregnancy is associated with an increased risk of serious adverse perinatal outcomes. The aim of our clinical prospective study was to evaluate the clinical effectiveness of preventive therapy in pregnant women with obesity and vitamin D deficiency. Pregnant patients with obesity were divided into clinical subgroups, depending on the dose of vitamin D preparation at the beginning of preventive therapy in accordance with the initial serum level of 25(OH)D. The first subgroup of the clinical group of the prospective study - 24 women who had a level of 25(OH)D in blood serum less than 22.0 ng/ml, in addition to low dose (100 mg per day) of acetylsalicylic acid (ASA) received vitamin D (4000 IU per day), the II-nd clinical subgroup consisted of 26 pregnant women who received ASA (100 mg per day) and vitamin D (2000 IU per day) with an initial serum concentration of 25(OH)D 22.1-28.0 ng/ml and III-d subgroup – 25 patients who received the low dose ASA and vitamin D (1000 IU per day), who had a serum 25(OH)D content of more than 28.1 ng/ml. Practically healthy pregnant women from the control group received 600 IU of vitamin D per day. The prescription of the drugs began at 10-12 weeks of pregnancy, and ended at 36 weeks of gestation. Variational and statistical processing of the research results was performed using the "STATISTICA 10" Enterprise Portable program. According to analysis of the clinical effectiveness of complex preventive therapy we found that a more positive effect was achieved with additional supplementation of vitamin D to pregnant women in a dose of 4000 IU (100 μg) per day with prior – the established level of 25(OH)D <20 nmol/l (12 ng/ml), against the appointment of 2000 IU of vitamin D (50 μg) to patients with a level of 25(OH)D of 20-30 nmol/l (8-12 ng/ml). The clinical effectiveness of the aforementioned preventive strategy was primarily a significant reduction in perinatal pathology cases (by 2 times), de novo hypertensive disorders (by 3.7 times), placental dysfunction (by 5.5 times) and fetal growth restriction (by 4.6 times), fetal distress (3.1 times), uterine subinvolution (3.7 times), postpartum septic complications (7.3 times), early neonatal adaptation disorders (2.5 times), newborn asphyxia (3, 2 times), as well as a significant decrease in cases of anomalies of labor activity (р=0.04), bacterial vaginosis (р=0.03). During and after using the proposed prophylactic therapy, there were no cases of side effects of the drugs, both on the part of the mother, and on the part of the fetus and newborn child.

show abstract

mentioning

confidence: 99%

“…2 Long-term outcomes include a wide variety of chronic diseases such as neurocognitive delay during childhood and increased risk of hypertension, type 2 diabetes mellitus, dyslipidemia, obesity, and cardiovascular disease during adulthood. [2][3][4] Despite the evidence regarding the association between FGR and adverse neonatal outcomes, 4 little is known about the association between FGR and adverse maternal outcomes. Due to the common pathophysiology of placental insufficiency, FGR is associated with a higher incidence of preeclampsia and vice versa.…”

mentioning

confidence: 99%

The Association between Fetal Growth Restriction and Maternal Morbidity

et al. 2023

View full text Add to dashboard Cite

Objective This study aimed to compare adverse maternal outcomes between pregnancies complicated by fetal growth restriction (FGR) and those without FGR. Study Design This was a secondary analysis of the data from the Consortium on Safe Labor, which was conducted from 2002 to 2008 in 12 clinical centers with 19 hospitals across 9 American College of Obstetricians and Gynecologists districts. We included singleton pregnancies without any maternal comorbidities or placenta abnormalities. We compared the outcomes of individuals with FGR with individuals without FGR. Our primary outcome was severe maternal morbidity. Our secondary outcome included various adverse maternal and neonatal outcomes. Multivariable logistic regression was performed to obtain adjusted odds ratios (aOR) and 95% confidence intervals (95% CI), adjusting for confounders. Missing values for maternal age and body mass index were imputed. Results Of 199,611 individuals, 4,554 (2.3%) had FGR and 195,057 (97.7%) did not have FGR. Compared with the individuals without FGR, individuals with FGR had increased odds of severe maternal morbidity (0.6 vs. 1.3%; aOR: 1.97 [95% CI: 1.51–2.57]), cesarean delivery (27.7 vs. 41.2%; aOR: 2.31 [95% CI: 2.16–2.48]), pregnancy-associated hypertension (8.3 vs. 19.2%; aOR: 2.76 [95% CI: 2.55–2.99]), preeclampsia without severe features (3.2 vs. 4.7%; aOR: 1.45 [95% CI: 1.26–1.68]), preeclampsia with severe features (1.4 vs. 8.6%; aOR: 6.04 [95% CI: 5.39–6.76]), superimposed preeclampsia (18.3 vs. 30.2%; aOR: 1.99 [95% CI: 1.53–2.59]), neonatal intensive care unit admission (9.7 vs. 28.4%; aOR: 3.53 [95% CI: 3.28–3.8]), respiratory distress syndrome (2.2 vs. 7.7%; aOR: 3.57 [95% CI: 3.15–4.04]), transient tachypnea of the newborn (3.3 vs. 5.4%; aOR: 1.62 [95% CI: 1.40–1.87]), and neonatal sepsis (2.1 vs. 5.5%; aOR: 2.43 [95% CI: 2.10–2.80]). Conclusion FGR was associated with increased odds of severe maternal outcomes in addition to adverse neonatal outcomes. Key Points

show abstract

Relationship of maternal obesity and vitamin D concentrations with fetal growth in early pregnancy

Cited by 14 publications

References 51 publications

The Gestational Effects of Maternal Bone Marker Molecules on Fetal Growth, Metabolism and Long-Term Metabolic Health: A Systematic Review

The Gestational Effects of Maternal Bone Marker Molecules on Fetal Growth, Metabolism and Long-Term Metabolic Health: A Systematic Review

The analysis of the clinical effectiveness of preventive therapy in pregnant women with moderate obesity and disorder of vitamin D metabolism

The Association between Fetal Growth Restriction and Maternal Morbidity

Contact Info

Product

Resources

About